先瑞達醫療今日暗盤,一手中籤率3%
先瑞達醫療 (06669) 公佈招股結果。內地醫療器械公司先瑞達醫療以每股23.8元定價,爲招股價範圍22.2元至23.8元上限,集資淨額15.3億元,一手中籤率3%,抽200手(200,000股)始可穩獲一手。先瑞達醫療將於8月24日掛牌。
先瑞達醫療於香港公開發售部分共錄得近31.1萬人認購,超額認購653.51倍,國際發售部分超額認購3.86倍。
集資所得款項32%將被分配予其核心產品(即AcoArt TulipTM & LitosTM及AcoArt Orchid® & DhaliaTM);23%分配予現有產品管線中餘下的24款產品;24%用於爲通過內部研發、合作、合併及收購、授權引進或股權投資等方式擴大產品組合提供資金;8%用於營運資金及一般企業用途;6%用於償還1月來自硅谷銀行的貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.